TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12716347

Group type: EXPERIMENTAL
Intervention: GR79236 (10 microg/kg i.v.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10922429

Group type: EXPERIMENTAL
Intervention: Simvastatin therapy (starting at 20 mg/day, titrated to 40 mg/day if cholesterol >5.2 mmol/L)
Number of subjects: 4444

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444

Group type: EXPERIMENTAL
Intervention: Simvastatin therapy
Number of subjects: 4444
Study: 8814503

Group type: EXPERIMENTAL
Intervention: Short-term high intensity (STHI) exercise at approximately 90-95% of VO2max
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Short-term high intensity (STHI) exercise
Number of subjects: 14
Study: 1348751

Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 10
Study: 30097419

Group type: EXPERIMENTAL
Intervention: iCBT intervention group
Number of subjects: 706

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 706
Study: 28499431

Group type: EXPERIMENTAL
Intervention: MIPPO
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional ORIF
Number of subjects: 36
Study: 26003436

Group type: EXPERIMENTAL
Intervention: Telehealth behavioral treatment (TBT)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Education only (EO)
Number of subjects: 194
Study: 23545912

Group type: EXPERIMENTAL
Intervention: Calcipotriene foam, 0.005%
Number of subjects: 363

Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 363
Study: 20877714

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL) treatment for fever in the intervention group
Number of subjects: 3125

Group type: EXPERIMENTAL
Intervention: Early and appropriate treatment with amoxicillin for nonsevere pneumonia in the intervention group
Number of subjects: 3125

Group type: COMPARATOR
Intervention: Control group treatment for fever
Number of subjects: 3125

Group type: COMPARATOR
Intervention: Control group treatment for nonsevere pneumonia
Number of subjects: 3125
Study: 19927606

Group type: EXPERIMENTAL
Intervention: Ferrous glycine phosphate and riboflavin added to school meals (28 mg of elemental iron and 1 mg of riboflavin per child per day) for 6 months.
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 136
Study: 16306925

Group type: EXPERIMENTAL
Intervention: Iron supplementation (10 mg daily for 6 months)
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg daily for 6 months)
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Combined iron and zinc supplementation (10 mg iron + 10 mg zinc daily for 6 months)
Number of subjects: 915

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 915
Study: 15451795

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 934

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 934

Group type: COMPARATOR
Intervention: Both
Number of subjects: 934
Study: 11426091

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 mg/kg) with 1% lidocaine infiltration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous normal saline (placebo)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1% lidocaine infiltration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 mg/kg) with normal saline infiltration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ketamine-lidocaine group (ketamine with 1% lidocaine infiltration)
Number of subjects: 40
Study: 9435930

Group type: EXPERIMENTAL
Intervention: Reports published in 1996
Number of subjects: 100

Group type: COMPARATOR
Intervention: Reports published between 1979 to 1984
Number of subjects: 100
Study: 8236005

Group type: EXPERIMENTAL
Intervention: ketorolac 0.5% ophthalmic solution
Number of subjects: 148

Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 148
Study: 3822295

Group type: EXPERIMENTAL
Intervention: Suprapubic bladder drainage
Number of subjects: 51

Group type: COMPARATOR
Intervention: Transurethral bladder drainage (Control)
Number of subjects: 51
Study: 31574339

Group type: EXPERIMENTAL
Intervention: Multiplex PCR results available in 24 hours (intervention group)
Number of subjects: 998

Group type: COMPARATOR
Intervention: Standard care with multiplex PCR results available in 7 days (control group)
Number of subjects: 998
Study: 29793518

Group type: EXPERIMENTAL
Intervention: Low-intensity, low-volume training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-intensity, high-volume training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-intensity, high-volume training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no supervised exercise)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 60
Study: 27803392

Group type: EXPERIMENTAL
Intervention: 3K3A-APC (study drug), dosage not specified, used in conjunction with intra-arterial therapy (IAT)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy (IAT)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Protocol amendment allowing IAT
Number of subjects: 51
Study: 22407197

Group type: EXPERIMENTAL
Intervention: Low-dose penicillin G
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: High-dose penicillin G
Number of subjects: 58

Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 58
Study: 22889883

Group type: EXPERIMENTAL
Intervention: Sequential radial artery grafts (Group A)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Single radial artery grafts (Group B)
Number of subjects: 53
Study: 20709856

Group type: EXPERIMENTAL
Intervention: SMART lunch box intervention
Number of subjects: 1291

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1291
Study: 19452729

Group type: EXPERIMENTAL
Intervention: Electronic laryngoscope (EL)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Self-retaining laryngoscope (SRM)
Number of subjects: 92
Study: 16102079

Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cav-Clean
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (dental adhesive only)
Number of subjects: 17
Study: 14620219

Group type: EXPERIMENTAL
Intervention: Holding a container of sucrose
Number of subjects: 76

Group type: COMPARATOR
Intervention: Not holding a container of sucrose (control)
Number of subjects: 76
Study: 10593548

Group type: EXPERIMENTAL
Intervention: Carbamazepine treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (unmedicated subjects with migraine headache)
Number of subjects: 10
Study: 8763594

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg 12-hourly for 8 days
Number of subjects: 280

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate 500 mg 8-hourly for 8 days
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 280

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate
Number of subjects: 280
Study: 1678033

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 4000 U calcium heparin over 4 hours
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of 12,500 U calcium heparin
Number of subjects: 8
Study: 6953729

Group type: EXPERIMENTAL
Intervention: Epidural pethidine (20 or 60 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Parenteral pethidine (2 mg/kg body weight intramuscularly)
Number of subjects: 6
Study: 31606398

Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT
Number of subjects: 273

Group type: COMPARATOR
Intervention: Internet-delivered pain education
Number of subjects: 273
Study: 29959448

Group type: EXPERIMENTAL
Intervention: Concentric cross-education (CE)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Eccentric cross-education (CE)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 48
Study: 28495412

Group type: EXPERIMENTAL
Intervention: Topaz® microdebridement
Number of subjects: 36

Group type: COMPARATOR
Intervention: Surgical decompression
Number of subjects: 36
Study: 25957574

Group type: EXPERIMENTAL
Intervention: Mobile coach based intervention (N = 840)
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Assessment only control group (N = 840)
Number of subjects: 1680
Study: 23374328

Group type: EXPERIMENTAL
Intervention: Micronized progesterone (400 mg/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 21397252

Group type: EXPERIMENTAL
Intervention: Slow wave deprivation (SWD)
Number of subjects: 17
Study: 18718971

Group type: EXPERIMENTAL
Intervention: Experimental quadriceps muscle pain induced by hypertonic saline (5.8%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control with isotonic saline (0.9%)
Number of subjects: 20
Study: 17760544

Group type: EXPERIMENTAL
Intervention: MM + SRP
Number of subjects: 127

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 127
Study: 14509050

Group type: EXPERIMENTAL
Intervention: Flupentixol
Number of subjects: 153

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 153
Study: 10611184

Group type: EXPERIMENTAL
Intervention: 150 IU daily fixed-dose regimen of recombinant follicle stimulating hormone (FSH, Puregon)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 250 IU daily fixed-dose regimen of recombinant follicle stimulating hormone (FSH, Puregon)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 250 IU daily fixed-dose regimen of recombinant follicle stimulating hormone (FSH, Puregon) in 30-33 age class
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 150 IU daily fixed-dose regimen of recombinant follicle stimulating hormone (FSH, Puregon) in 37-39 age class
Number of subjects: 138
Study: 9104664

Group type: EXPERIMENTAL
Intervention: Research-based clinical handbook for continence care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no handbook)
Number of subjects: 0
Study: 1359808

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2.4 micrograms/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.2 micrograms/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 100
Study: 3510601

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide hydrochloride
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study: 29727719

Group type: EXPERIMENTAL
Intervention: Breathing-Stacking (BS)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Incentive Spirometer (IS)
Number of subjects: 14
Study: 26369589

Group type: EXPERIMENTAL
Intervention: Albuterol MDPI 180 µg (2 inhalations × 90 µg/inhalation) 4 times/day for 12 weeks
Number of subjects: 654

Group type: COMPARATOR
Intervention: Placebo MDPI
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Albuterol MDPI 180 µg (2 inhalations × 90 µg/inhalation) as needed (PRN) during the 40-week open-label phase
Number of subjects: 654
Study: 24799585

Group type: EXPERIMENTAL
Intervention: Providing full drug coverage for nonwhite patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Providing full drug coverage for white patients
Number of subjects: 0
Study: 22672221

Group type: EXPERIMENTAL
Intervention: Improved glycemic control (mean HbA1c decreased by 13% to 8 ± 1.6%)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Improved glycemic control (cholesterol decreased by 17% to 4.3 ± 1.3 mmol/L)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Improved glycemic control
Number of subjects: 27
Study: 20199979

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2 plus carboplatin AUC 6
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2 plus oxaliplatin 120 mg/m2
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Pemetrexed treatment
Number of subjects: 130
Study: 18832488

Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 16081445

Group type: EXPERIMENTAL
Intervention: Daily multivitamin and multimineral supplementation
Number of subjects: 910

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 910
Study: 11777511

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexamethasone 16 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 10388143

Group type: EXPERIMENTAL
Intervention: Physical disability
Number of subjects: 1104

Group type: EXPERIMENTAL
Intervention: Physical disability (limited to those in intact or partially-destroyed dwellings)
Number of subjects: 1104

Group type: EXPERIMENTAL
Intervention: Age and degree of damage to dwelling
Number of subjects: 1104
Study: 8681492

Group type: EXPERIMENTAL
Intervention: Captopril, 25 mg three times a day for 7 days
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 7
Study: 2021381

Group type: EXPERIMENTAL
Intervention: False skin conductance feedback during CS presentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-report and behavioral measures of UCS revaluation after conditioning
Number of subjects: 0
Study: 6129867

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 136

Group type: COMPARATOR
Intervention: Clemastine
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 31183797

Group type: EXPERIMENTAL
Intervention: neoClose® device
Number of subjects: 35

Group type: COMPARATOR
Intervention: standard suture passer
Number of subjects: 35
Study: 31086334

Group type: EXPERIMENTAL
Intervention: Imprisonment
Number of subjects: 111110

Group type: COMPARATOR
Intervention: Probation
Number of subjects: 111110
Study: 28222251

Group type: EXPERIMENTAL
Intervention: Hypomethylation of LZTS2
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Hypomethylation of NR6A1
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Methylation values below the median at both markers
Number of subjects: 295
Study: 24408881

Group type: EXPERIMENTAL
Intervention: Simultaneous compression with Fixed cycling rate (SF)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Alternate compression with Adjusted cycling rate (AA)
Number of subjects: 108
Study: 24297763

Group type: EXPERIMENTAL
Intervention: Robotic therapy (12 hours)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional therapy (12 hours)
Number of subjects: 12
Study: 22194152

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation
Number of subjects: 1813

Group type: COMPARATOR
Intervention: Usual care (without referral to rehabilitation)
Number of subjects: 1813
Study: 19192016

Group type: EXPERIMENTAL
Intervention: Cream containing 6.0% Stryphnodendron adstringens bark extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17943982

Group type: EXPERIMENTAL
Intervention: Dental roll with one mini-marshmallow
Number of subjects: 65

Group type: COMPARATOR
Intervention: Flavored drink crystal dental rolls
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Marshmallow-flavored dental rolls
Number of subjects: 65
Study: 16002033

Group type: EXPERIMENTAL
Intervention: Daily IVR monitoring for 28 days
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Weekly IVR monitoring for 4 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: 28-day follow-up assessment with retrospective drinking reports
Number of subjects: 98
Study: 12360595

Group type: EXPERIMENTAL
Intervention: Berodual
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Salgim
Number of subjects: 32
Study: 9835059

Group type: EXPERIMENTAL
Intervention: High frequency (HF) words with differential strengthening during list presentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low frequency (LF) words
Number of subjects: 0
Study: 7917196

Group type: EXPERIMENTAL
Intervention: Prednisone therapy taper from 60 mg orally decreasing by 10 mg each day over 6 days
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 2490831

Group type: EXPERIMENTAL
Intervention: Increased treatment of hypertension (antihypertensive medication)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community control of hypertension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall treatment of hypertension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Factors other than antihypertensive treatment
Number of subjects: 0
Study: 7001039

Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis administered at intervals of 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis
Number of subjects: 0
Study: 31542381

Group type: EXPERIMENTAL
Intervention: sealed meal and snack condition
Number of subjects: 62

Group type: COMPARATOR
Intervention: pre‐opened meal and snack condition
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: sealed breakfast
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: high protein snack (cheese and biscuits)
Number of subjects: 62
Study: 30037726

Group type: EXPERIMENTAL
Intervention: ACR of 30 to 299 mg/g
Number of subjects: 3511

Group type: EXPERIMENTAL
Intervention: ACR ≥ 300 mg/g
Number of subjects: 3511
Study: 28059560

Group type: EXPERIMENTAL
Intervention: Hippocampal sparing intensity-modulated radiotherapy (HS IMRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional whole-brain radiotherapy (WBRT)
Number of subjects: 0
Study: 24953533

Group type: EXPERIMENTAL
Intervention: Computer reminders (ComRem)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Postal reminders (Postal)
Number of subjects: 213
Study: 23414904

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control (no RIPC)
Number of subjects: 205
Study: 21324607

Group type: EXPERIMENTAL
Intervention: Alcohol Ladder (AL) at 3 months post release
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Alcohol Ladder (AL) at baseline
Number of subjects: 114
Study: 19352063

Group type: EXPERIMENTAL
Intervention: BCAA drink (0.4% BCAA, 4% carbohydrate; 1,500 mL/d)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo drink (iso‐caloric)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BCAA drink
Number of subjects: 8
Study: 18186378

Group type: EXPERIMENTAL
Intervention: Clinical examination alone (OBS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Appendiceal CT scan with clinical observation (CT)
Number of subjects: 90
Study: 16331300

Group type: EXPERIMENTAL
Intervention: Hypo-energetic low-fat diet (20-25% fat energy, -600 kcal/day)
Number of subjects: 771

Group type: COMPARATOR
Intervention: Hypo-energetic high-fat diet (40-45% fat energy, -600 kcal/day)
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 771
Study: 14668779

Group type: EXPERIMENTAL
Intervention: LIMA to LAD anastomosis with stress-induced ischemia
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Patients with luminal stenosis
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Patients with ILAD without luminal stenosis
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (18 subjects without ischemia or stenosis)
Number of subjects: 38
Study: 10321931

Group type: EXPERIMENTAL
Intervention: Alendronate 40 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etidronate and calcitonin (control)
Number of subjects: 0
Study: 9110064

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (500 mg six times daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir (5 mg/kg once daily)
Number of subjects: 100
Study: 1748537

Group type: EXPERIMENTAL
Intervention: Soft gelatin capsule
Number of subjects: 14

Group type: COMPARATOR
Intervention: Liquid prepared from effervescent IP tablets
Number of subjects: 14

Group type: COMPARATOR
Intervention: Film-coated tablet
Number of subjects: 14
Study: 7183193

Group type: EXPERIMENTAL
Intervention: Smokers who consumed more food or liquids to avoid smoking and/or avoided related substances such as alcohol and coffee
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Smokers who attempted to reduce without a specific plan
Number of subjects: 24
Study: 29484547

Group type: EXPERIMENTAL
Intervention: New complete dentures (T2)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: New complete dentures (T3)
Number of subjects: 32
Study: 27578231

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron 4mg in 10mL of saline
Number of subjects: 100

Group type: COMPARATOR
Intervention: 10mL of saline (placebo)
Number of subjects: 100
Study: 24570141

Group type: EXPERIMENTAL
Intervention: High-fat overfeeding diet for 5 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 40
Study: 23378709

Group type: EXPERIMENTAL
Intervention: Low-fluence Q-switched Nd: YAG laser (QSNYL) at weekly intervals
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical 20% azelaic acid cream applied twice daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of low-fluence QSNYL and topical 20% azelaic acid cream
Number of subjects: 60
Study: 20529547

Group type: EXPERIMENTAL
Intervention: Low dose potassium sodium hydrogen citrate (1 g/d)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: High dose potassium sodium hydrogen citrate (2 g/d)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No potassium sodium hydrogen citrate (control group)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both doses of PSHC (1 g/d and 2 g/d)
Number of subjects: 72
Study: 18672630

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 382

Group type: COMPARATOR
Intervention: metoclopramide 10 mg
Number of subjects: 382
Study: 15754988

Group type: EXPERIMENTAL
Intervention: Fiducial marker fitting with parameter distribution model (PDM)
Number of subjects: 13
Study: 12486491

Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) 800 mg infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study: 10351919

Group type: EXPERIMENTAL
Intervention: Formoterol (12 micrograms)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Albuterol (200 micrograms)
Number of subjects: 16